Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables) - Warrants to Purchase Common Stock [Member]

3 Months Ended

Mar. 31, 2024

Schedule of revaluation of warrant liability


		Warrants
($ in thousands)		liabilities
Balance at December 31, 2023		$	886
Change in fair value of common stock warrants - Avenue			116
Change in fair value of common stock warrants - Checkpoint			—
Change in fair value of placement agent warrants - Urica			(24)
Exercise of common stock warrants - Avenue			(289)
Balance at March 31, 2024		$	689

Checkpoint Common Stock Warrants

Summary of the Weighted average Significant Unobservable Inputs


		March 31,			December 31,
Checkpoint Warrants		2024			2023
Exercise price		$	5.41		$	5.41
Volatility			107.5	%		96.4	%
Expected life			3.7			4.0
Risk-free rate			4.2	%		3.8	%

Avenue Therapeutics, Inc [Member]

Schedule of revaluation of warrant liability


		Avenue
		Warrant
($ in thousands)		Liability
Common Stock Warrant liabilities at December 31, 2023		$	586
Exercise of Avenue common warrants			(289)
Change in fair value of common stock warrant liabilities			116
Common Stock Warrant liabilities at March 31, 2024		$	413

Summary of the Weighted average Significant Unobservable Inputs


		March 31,			December 31
		2024			2023
Stock price		$ 11.10			$ 12.00
Risk-free interest rate		4.21	%		3.84	%
Expected dividend yield		—			—
Expected term in years		3.50			3.80
Expected volatility		162	%		148	%

Summary of the Weighted average Significant Unobservable Inputs


		March 31,			December 31,
		2024			2023
Risk-free interest rate		4.33	%		3.93	%
Expected dividend yield		—			—
Expected term in years		0.25			0.5
Expected volatility		102.3	%		153.6	%